Results 41 to 50 of about 2,636,203 (317)
Next Step in Chronic Kidney Disease Therapy
Počki, 2016 Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers are the basis of renoprotection therapy in chronic kidney disease. Parallel to decrease of glomerular filtration rate, there is an increase in the activity of the sympathetic nervous ...
D.D. Ivanov
doaj +1 more source
PPAR Research, 2020 The activation of the renin-angiotensin system (RAS) participates in the development of metabolic syndrome (MetS) and in heart failure. PPAR-alpha activation by fenofibrate reverts some of the effects caused by these pathologies.
María Sánchez-Aguilar +7 more
doaj +1 more source
Case Reports in Nephrology, 2020 The renin-angiotensin system plays a very critical role in hypertension, diabetes, and kidney and heart diseases. The blockade of the renin-angiotensin system results in the prevention of progression of renal and cardiac damage.
Avantika Chenna +7 more
doaj +1 more source
Intraoperative angioedema induced by angiotensin II receptor blocker: a case report
Patient Safety in Surgery, 2018 Background Angiotensin II receptor blockers are a class of antihypertensive agent that is developed to exclude the adverse effects of angiotensin converting enzyme inhibitors.
Ala”a Alhowary +3 more
doaj +1 more source
Losartan Improves Memory, Neurogenesis and Cell Motility in Transgenic Alzheimer’s Mice
Pharmaceuticals, 2021 Angiotensin receptor blockers (ARBs) have demonstrated multiple neuroprotective benefits in Alzheimer’s disease (AD) models. However, their beneficial effects on memory deficits, cholinergic activity, neurogenesis and Amyloid beta (Aβ) clearance reveal ...
Henning Johannes Drews +13 more
doaj +1 more source
Hypertension Hot Potato - Anatomy of the Angiotensin-Receptor Blocker Recalls.
New England Journal of Medicine, 2019 Hypertension Hot Potato A spate of recalls of angiotensin-receptor blockers highlights several issues related to the readiness of our health systems to respond to drug recalls, trust between patients and providers, uncertain drug-dose equivalences, and ...
J. B. Byrd, G. Chertow, Vivek Bhalla
semanticscholar +1 more source
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
New England Journal of Medicine, 2014 BACKGROUND We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients.
J. McMurray +10 more
semanticscholar +1 more source
FEBS Letters, EarlyView.Angiotensin II (AngII), a neuropeptide, interacts with amyloid‐β (Aβ), a key player in Alzheimer's disease. This study reveals that AngII reduces Aβ aggregation and membrane disruption in vitro. Biophysical assays and molecular modeling suggest AngII binds disordered Aβ forms, potentially modulating early amyloidogenic events and contributing to ...
Mohsen Habibnia +5 more
wiley +1 more source
JAMA Network Open, 2019 Key Points Question Are angiotensin receptor blockers associated with a higher risk of suicide than angiotensin-converting enzyme inhibitors? Findings In this case-control study of 964 older adults who died by suicide and 3856 matched control ...
M. Mamdani +7 more
semanticscholar +1 more source
Reciprocal control of viral infection and phosphoinositide dynamics
FEBS Letters, EarlyView.Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley +1 more source